BiotechTube

Ruxolitinib + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

MPN (Myeloproliferative Neoplasms)

Conditions

MPN (Myeloproliferative Neoplasms)

Trial Timeline

Aug 1, 2009 → Oct 1, 2015

NCT ID
NCT00952289

About Ruxolitinib + Placebo

Ruxolitinib + Placebo is a phase 3 stage product being developed by Incyte for MPN (Myeloproliferative Neoplasms). The current trial status is completed. This product is registered under clinical trial identifier NCT00952289. Target conditions include MPN (Myeloproliferative Neoplasms).

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00952289Phase 3Completed

Competing Products

6 competing products in MPN (Myeloproliferative Neoplasms)

See all competitors
ProductCompanyStageHype Score
RuxolitinibIncytePhase 2
49
Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + ParsaclisibIncytePhase 2
49
Ruxolitinib + Anagrelide + Placebo + PlaceboIncytePhase 2
49
itacitinibIncytePhase 2
49
PemigatinibIncytePhase 2
49
Itacitinib + RuxolitinibIncytePhase 2
49

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74